{
    "Trade/Device Name(s)": [
        "CR3 Keyless Split Sample Cup Nortriptyline\u2013Buprenorphine"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K142609",
    "Predicate Device Reference 510(k) Number(s)": [
        "K132812"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFG",
        "DJG"
    ],
    "Summary Letter Date": "October 13, 2014",
    "Summary Letter Received Date": "October 16, 2014",
    "Submission Date": "December 10, 2014",
    "Regulation Number(s)": [
        "21CFR862.3910",
        "21CFR862.3650"
    ],
    "Regulation Name(s)": [
        "Tricyclic antidepressant drugs test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Nortriptyline",
        "Buprenorphine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Cup"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow assay"
    ],
    "Methodologies": [
        "Competitive binding",
        "Antigen-antibody immunochemistry"
    ],
    "Submission Type(s)": [
        "Specimen collection device"
    ],
    "Document Summary": "FDA 510(k) summary for CR3 Keyless Split Sample Cup Nortriptyline\u2013Buprenorphine rapid lateral flow assay for qualitative detection of nortriptyline and buprenorphine in urine.",
    "Indications for Use Summary": "Rapid qualitative detection of nortriptyline (tricyclic antidepressant metabolite) and buprenorphine in human urine at cutoff concentrations of 1000 ng/mL and 10 ng/mL respectively, as the first step in a two-step process for drugs of abuse screening in over-the-counter and prescription settings.",
    "fda_folder": "Toxicology"
}